List view / Grid view
With insight from industry leaders, this exclusive online monthly series explores the key developments, challenges and opportunities of microbiome therapeutics, spanning a range of topics from clinical stage development though to manufacturing, regulation and quality control in the pharmaceutical industry.
Increasing prevalence of conditions such as metabolic, gastrointestinal and infectious diseases in recent years has resulted in greater interest in digestive health from both the public and pharmaceutical industry, heightening the demand for microbiome therapeutics such as live biotherapeutic products (LBPs) and faecal matter transplants (FMT) treatments.
In the fourth instalment of EPR's ‘Microbiome therapeutics: microscope to medicine’ series, Emilie Plantamura, Deputy Chief Medical Officer at MaaT Pharma, examines the promising potential of microbiome therapeutics beyond Clostridium difficile infection, particularly in the onco-haematological field.
In our third instalment of EPR's exclusive ‘Microbiome therapeutics: microscope to medicine’ series, Tue Hodal, Chief Technology Officer and Lorenz Rindisbacher, Chief Quality Officer, Bacthera, explore how live biotherapeutic products (LBPs) represent a transformative shift in medicine, highlighting their unique challenges and potential.
Here, Chief Technical Officer, Mike Frodsham and Ryan Wilson, Head of Microbiome Services at SGS Quay Pharma, explore the chemistry, manufacturing, and control (CMC) challenges of developing drug products containing live anaerobic bacterial strains, used for treatments such as microbiome therapeutics.
Here, Chrysi Sergaki from the Medicines and Healthcare products Regulatory Agency (MHRA), UK, explores how innovators and regulators can navigate the challenges affecting the development and regulation of microbiome therapeutics to bring safe and efficacious therapies to patients as soon as possible.
